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Thank you for your comments regarding our manuscript enti-
tled “Effects of rosiglitazone on inflammation in Otsuka Long-
Evans Tokushima Fatty rats,” which was published in Korean 
Diabetes J 2010;34:191-9. The authors appreciate your construc-
tive and helpful comments. We have responded to the questions 
below. 
  Thiazolidinediones (TZD), including rosiglitazone, are high-
affinity ligands for peroxisome proliferator–activated receptors-
gamma (PPAR-γ) and are used as insulin-sensitizing drugs [1]. 
PPAR-γ is predominantly expressed in adipose tissue, whereas 
the improvement in insulin sensitivity after TZD treatment 
occurs mainly in skeletal muscle where PPAR-γ expression is 
relatively low [2]. Therefore, it has been suggested that TZD 
improves peripheral insulin action by modulating communi-
cation signals, such as adiponectin [3], leptin [4] and tumor 
necrosis factor-alpha (TNF-α) [5], between fat and muscle. 
Another explanation is that TZD improves insulin sensitivity 
by promoting the redistribution of triglycerides from the liver 
and muscle to the adipose tissue [6,7]. Many studies have re-
ported that PPAR-γ agonists result in lipid storage coupled 
with the reduced release of free fatty acids (FFA) into the circu-
lation and also increase subcutaneous adiposity but have no 
effect on visceral fat mass [8].
  In the studies on Otsuka Long-Evans Tokushima fatty 
(OLETF) rats, PPAR-α activators, including bezafibrate and 
rosiglitazone, greatly suppressed the expression of proinflam-
matory cytokines such as TNF-α, interleukin (IL)-1β and IL-
6, and α-smooth muscle actin (SMA) in the pancreas [7,8]. In 
our study, we investigated the effects of the insulin-sensitizing 
anti-diabetic agent rosiglitazone on the progression of skeletal 
muscle inflammation in OLETF rats. We found that rosigli-
tazone decreased the concentrations of glucose, insulin and 
inflammatory cytokines in the sera of OLETF rats. Rosigli-
tazone also inhibited mRNA expression of inflammatory cyto-
kines in skeletal muscle by blocking the NF-κB pathway. There-
fore, our findings suggest that rosiglitazone may improve in-
sulin sensitivity with its anti-inflammatory activity in the skel-
etal muscle of diabetic rats. 
  Our results concur with the findings of previous studies that 
PPAR-γ agonists can improve inflammation in peripheral tis-
sues (including the muscle and pancreas) via the inhibition of 
inflammatory signaling pathways [9,10]. Recently, TZD was 
discovered to have anti-inflammatory effects, and its potential 
was reevaluated for treating diabetes. Several studies have re-
ported that TZD including rosiglitazone decreases serum lev-
els of inflammatory makers TNF-α, IL-6, C-reactive protein 
(CRP), and FFAs in an experimental model of induced type 2 
diabetes in high-fat-diet albino rats [11,12]. In our study, FFA 
levels were lower in the OLETF group compared to the LETO 
group at the 40th week (Fig. 1). In contrast, we observed no 
decrease in FFA levels in the group treated with rosiglitazone. 
We still do not know why rosiglitazone did not decrease se-
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rum FFA concentrations in the stage of insulin resistance of 
OLETF rats. 
  Furthermore, the anti-inflammatory effects of rosiglitazone 
that block the inflammatory pathway in skeletal muscle inflam-
mation in diabetic and insulin-resistant patients without exces-
sive FFA influx into the skeletal muscle are not clear. Due to the 
link between insulin resistance and inflammatory processes, 
we suggest that therapeutic strategies to limit inflammation 
and reduce levels of inflammatory markers may be a promis-
ing tool in reducing symptoms in such patients [13,14].
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Fig. 1.  Changes in concentration of serological markers in 
LETO and OLETF rats. Free fatty acid levels in the sera of 
LETO or OLETF rats were measured by colorimetric and en-
zymatic assay at 28 and 40 weeks. Values are represented as 
mean ± standard deviation. 
aP < 0.05 as compared to each 
group. ROSI, rosiglitazone; FFA, free fatty acid (From Lee JW, 
et al. Korean Diabetes J 2010;34:191-9).